Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy.

BACKGROUND Platelet microparticles (PMPs), are procoagulant membrane vesicles that are derived from activated platelets, the levels of which are elevated in patients with hypertension, coronary artery disease (CAD), diabetes, and stroke, all of which are conditions that lead to (and are associated with) atrial fibrillation (AF). We hypothesized the following: (1) PMP levels are elevated in patients with AF compared to levels in both healthy control subjects (ie, patients without cardiovascular diseases who are in sinus rhythm) and disease control subjects (ie, patients with hypertension, CAD, diabetes or stroke, but who are in sinus rhythm); (2) PMP levels correlate with levels of soluble P-selectin (sP-selectin) [a marker of platelet activation]; and (3) PMP levels are related to the underlying factors in patients with AF that contribute to the overall risk of stroke secondary to AF. METHODS We performed a case-control study of 70 AF patients, 46 disease control subjects and 33 healthy control subjects. Peripheral venous levels of PMP and sP-selectin were analyzed by flow cytometry and enzyme-linked immunosorbent assay, respectively. RESULTS Both AF patients and disease control subjects had significantly higher levels of PMPs (p < 0.001) and sP-selectin (p = 0.001) compared to healthy control subjects, but there was no difference between AF patients and disease control subjects. There was no difference in PMP levels between patients with paroxysmal and permanent AF (p = 0.581), and between those receiving therapy with aspirin and warfarin (p = 0.779). No significant correlation was observed between PMP and sP-selectin levels (p = 0.463), and the clinical characteristics that contribute to increased stroke risk in patients with AF. On stepwise multiple regression analysis in the combined cohort of AF patients plus disease control subjects, the presence/absence of AF was not an independent determinant of PMP and sP-selectin levels. CONCLUSION There is evidence of platelet activation (ie, high PMP and sP-selectin levels) in AF patients, but this is likely to be due to underlying cardiovascular diseases rather than the arrhythmia per se.

[1]  Joyce Curvers,et al.  Effects of storage‐induced platelet microparticles on the initiation and propagation phase of blood coagulation , 2006, British journal of haematology.

[2]  L. Horstman,et al.  Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. , 2006, The American journal of cardiology.

[3]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[4]  R. D. de Winter,et al.  P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. , 2006, Clinical chemistry.

[5]  C. Sáez,et al.  Circulating platelet-derived microparticles in systemic lupus erythematosus , 2005, Thrombosis and Haemostasis.

[6]  G. Lip,et al.  Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation , 2005, Platelets.

[7]  Klaus Ley,et al.  The platelet microparticle proteome. , 2005, Journal of proteome research.

[8]  A. Castellanos,et al.  Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. , 2005, Heart rhythm.

[9]  G. Lip,et al.  Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers , 2005, Annals of medicine.

[10]  G. Lip,et al.  Angiogenic factors in atrial fibrillation: A possible role in thrombogenesis? , 2005, Annals of medicine.

[11]  T. Iwasaka,et al.  Effect of Ticlopidine on Monocyte-derived Microparticles and Activated Platelet Markers in Diabetes Mellitus , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[12]  S. Pfister.  Role of Platelet Microparticles in the Production of Thromboxane by Rabbit Pulmonary Artery , 2004, Hypertension.

[13]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[14]  K. Kosmelj,et al.  High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy , 2003, Thrombosis and Haemostasis.

[15]  G. Mensah,et al.  Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999: Implications for Primary Prevention , 2003, Circulation.

[16]  P. Walsh,et al.  The Glycoprotein Ib-IX-V Complex Mediates Localization of Factor XI to Lipid Rafts on the Platelet Membrane* , 2003, Journal of Biological Chemistry.

[17]  L. Horstman,et al.  High levels of circulating endothelial microparticles in patients with acute coronary syndromes. , 2003, American heart journal.

[18]  K. Preissner,et al.  Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  Richard A. Preston,et al.  Effects of Severe Hypertension on Endothelial and Platelet Microparticles , 2003, Hypertension.

[20]  G. Lip,et al.  Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors , 2002, Circulation.

[21]  G. Lip,et al.  Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor? , 2002, Stroke.

[22]  Y. J. Lee,et al.  Optimized flow cytometric assay for the measurement of platelet microparticles in plasma: pre-analytic and analytic considerations , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  G. Lip,et al.  Platelet P-Selectin Levels in Relation to Plasma Soluble P-Selectin and &bgr;-Thromboglobulin Levels in Atrial Fibrillation , 2002, Stroke.

[24]  T. Podor,et al.  Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface* , 2002, The Journal of Biological Chemistry.

[25]  José A. López,et al.  Factor XI Binding to the Platelet Glycoprotein Ib-IX-V Complex Promotes Factor XI Activation by Thrombin* , 2002, The Journal of Biological Chemistry.

[26]  A. Tedgui,et al.  Circulating Microparticles From Patients With Myocardial Infarction Cause Endothelial Dysfunction , 2001, Circulation.

[27]  G. Lip,et al.  Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. , 2001, European heart journal.

[28]  D. Brindley,et al.  Platelet-released phospholipids link haemostasis and angiogenesis. , 2001, Cardiovascular research.

[29]  M. Koksch,et al.  P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[30]  S. Nomura,et al.  Effect of Ticlopidine on Platelet-Derived Microparticles in Patients with Connective Tissue Diseases , 2000, Pathophysiology of Haemostasis and Thrombosis.

[31]  M. Cushman,et al.  Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. , 1999, Stroke.

[32]  L. Horstman,et al.  Platelet microparticles: a wide-angle perspective. , 1999, Critical reviews in oncology/hematology.

[33]  M. Hori,et al.  Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. , 1998, Circulation.

[34]  G. FitzGerald,et al.  Modulation of monocyte-endothelial cell interactions by platelet microparticles. , 1998, The Journal of clinical investigation.

[35]  A. Goodall,et al.  European Working Group on Clinical Cell Analysis: Consensus Protocol for the Flow Cytometric Characterisation of Platelet Function , 1998, Thrombosis and Haemostasis.

[36]  K. Berkin,et al.  Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. , 1997, Heart.

[37]  G. Lip,et al.  Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. , 1996, Circulation.

[38]  L. Horstman,et al.  Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. , 1993, Thrombosis research.

[39]  J. Griffin,et al.  Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. , 1991, Blood.

[40]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.

[41]  H. Inagaki,et al.  Effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity in patients with atrial fibrillation. , 1987, Japanese heart journal.

[42]  I. Sotobata,et al.  Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. , 1986, Japanese heart journal.

[43]  W. Kannel,et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.

[44]  Steven J Edwards,et al.  Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. , 2006, Thrombosis research.

[45]  G. Lip,et al.  Is atrial fibrillation an inflammatory disorder? , 2006, European heart journal.

[46]  G. Lip.  The prothrombotic state in atrial fibrillation: the atrium, the endothelium... And tissue factor? , 2003, Thrombosis research.

[47]  M. Blombäck,et al.  Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. , 1990, Stroke.